Abstract
The eye is considered as the best targeted organ for gene therapy, which has become a hot field of ophthalmic clinical trials in recent years. Since the risk of gene therapy is usually high, it is important to standardize the ethical review of related clinical research, so as to better protect the rights of patients and promote the innovative research. Thus, after several rounds of discussion, the experts from Chinese Vitreo-Retina Society of Chinese Medical Association and Fundus Disease Committee of Chinese Ophthalmologist Association have proposed the formal ethical review guidelines (International Practice Guideline Registration Number: IPGRP-2022CN347), which would play a role in standardizing clinical practice with gene therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
